Holen Sie sich die Stockscreener-App
20.91
4.81%
0.96
Handel nachbörslich:
20.91
Schlusskurs vom Vortag:
$19.95
Offen:
$19.82
24-Stunden-Volumen:
93,173
Relative Volume:
1.16
Marktkapitalisierung:
$873.57M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+1.55%
1M Leistung:
+11.16%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$19.39
$21.18
1-Wochen-Bereich:
$19.39
$22.18
52-Wochen-Spanne:
$16.17
$26.25
Zenas Biopharma Inc Stock (ZBIO) Company Profile
Firmenname
Zenas Biopharma Inc
Sektor
Branche
Telefon
-
Adresse
-
Zenas Biopharma Inc Aktie (ZBIO) Neueste Nachrichten
Zenas Bio: Recent IPO With Late-Stage Candidate (NASDAQ:ZBIO) - Seeking Alpha
Zenas started at buy by four banks on lead drug potential (NASDAQ:ZBIO) - Seeking Alpha
Zenas stock backed by Guggenheim on strong outlook for lead drug obexelimab - Investing.com Canada
Morgan Stanley bullish on Zenas Biopharma stock as obexelimab trials gain momentum - Investing.com Canada
Citi sees upside in Zenas Biopharma stock as obexelimab progresses in key trials - Investing.com Canada
Jefferies bullish on Zenas stock as obexelimab advances in autoimmune trials - Investing.com Canada
Biopharma financings surge to $86.2B in 2024, with $8.7B in September - BioWorld Online
Halda appoints new chief executive - The Pharma Letter
IgG4-related Disease Market to Show Remarkable Growth Trends - openPR
Last Week's 3 Biotech IPOs Prompt Huge Insider Buying - 24/7 Wall St.
Biotech IPO Shares Climb in Debuts After Deals Upsized - MSN
Zenas BioPharma CEO acquires $360k worth of company shares - Investing.com India
Zenas BioPharma CEO acquires $360k worth of company shares By Investing.com - Investing.com South Africa
Zenas BioPharma’s $225 Million IPO - Global Legal Chronicle
Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in Initial Public Offering - The Korea Bizwire
Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase ... - The Bakersfield Californian
Zenas BioPharma Announces Closing of Full Exercise of - GlobeNewswire
Zenas BioPharma Announces Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares in - EIN News
Upstream Bio goes public amid spate of IPOs - The Pharma Letter
Zenas BioPharma sees $15 million in stock purchases by Zebra Aggregator - Investing.com South Africa
Zenas BioPharma director acquires $999k in company stock By Investing.com - Investing.com South Africa
Zenas BioPharma director acquires $999k in company stock - Investing.com Canada
IPOs, GLP-1 vs. PD-1, and AI in biotech: a BioCentury podcast - BioCentury
Zenas BioPharma director buys $7.48m in company stock By Investing.com - Investing.com South Africa
Zenas BioPharma director buys $7.48m in company stock - Investing.com
Zenas BioPharma director Jason Raleigh acquires $15 million in company stock By Investing.com - Investing.com South Africa
Zenas BioPharma director Jason Raleigh acquires $15 million in company stock - Investing.com India
Fairmount Healthcare Fund II L.P. buys $5.1m of Zenas BioPharma stock - Investing.com India
SR One Capital management buys $38m of Zenas BioPharma stock - Investing.com Australia
MBX, Zenas And Bicara IPOs Generate Big First Day Returns, But Will They Last? - Scrip
Biotech IPO Shares Climb in Trading Debuts After Deals Upsized - MSN
Biotech IPO Shares Climb in Trading Debuts After Deals Upsized | Stock Market News - Mint
Biotech IPOs Surge on Debut: Upsized Deals Boost Shares for Drug Developers Tackling Autoimmune Diseases - Share Price India News
Trio of first-day pops may bode well for biotech IPO window - BioCentury
Biotech Startups Make Pre-Election Sprint to the Public Markets - The Wall Street Journal
2 Life Sciences Cos. Start Trading After Raising $540M Total - Law360
Biotech trio revives the IPO market - Axios
3 Biotech IPOs, $703M Raised for Clinical Trials in Cancer, Immunology & Endocrine Disorders - MedCity News
Shares of two Mass. biotech IPOs rise on first day of trading - The Business Journals
Finanzdaten der Zenas Biopharma Inc-Aktie (ZBIO)
Es liegen keine Finanzdaten für Zenas Biopharma Inc (ZBIO) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Zenas Biopharma Inc-Aktie (ZBIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| MOULDER LEON O JR | Chief Executive Officer |
Sep 20 '24 |
Buy |
18.45 |
5,000 |
92,270 |
1,672,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Sep 19 '24 |
Buy |
17.89 |
5,000 |
89,450 |
1,667,039 |
| Enavate Sciences GP, LLC | 10% Owner |
Sep 16 '24 |
Buy |
17.00 |
882,353 |
15,000,001 |
3,761,359 |
| Lu Hongbo | Director |
Sep 13 '24 |
Buy |
17.00 |
58,823 |
999,991 |
58,823 |
| ENRIGHT PATRICK G | Director |
Sep 16 '24 |
Buy |
17.00 |
440,000 |
7,480,000 |
774,530 |
| Nunn Jason Raleigh | Director |
Sep 16 '24 |
Buy |
17.00 |
882,352 |
14,999,984 |
1,946,564 |
| Fairmount Funds Management LLC | Director |
Sep 16 '24 |
Buy |
17.00 |
300,000 |
5,100,000 |
1,604,891 |
| SR ONE CAPITAL MANAGEMENT, LLC | 10% Owner |
Sep 16 '24 |
Buy |
17.00 |
2,235,294 |
37,999,998 |
1,946,564 |
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):